abstract: OBJECTIVE: To evaluate a contribution of selected laboratory parameters for a prediction of progressive and erosive development in @entity1 with early @entity309 ( @entity309 ). METHODS: In a prospective study baseline levels of antibodies to cyclic citrullinated peptide (anti-CCP), IgM, IgA, and IgG rheumatoid factors (RFs) were measured by enzyme linked immunosorbent assay (ELISA) in 104 @entity1 with @entity309 with disease duration <2 years. Antikeratin antibodies (AKA) and antiperinuclear factor (APF) were detected by indirect immunofluorescence. @entity1 were divided into two groups based either on the presence or absence of erosions or according to progression of Larsen score at the end of the 24 months' follow up. RESULTS: Sixty seven (64%) @entity1 developed radiographic erosions, 49 (47%) had progression in Larsen score, and 36 (35%) progressed by more than 10 Larsen units. Significant differences in erosions and progression between the two groups were detected for anti-CCP, AKA, APF, IgM RF, IgA RF, and IgG RF. Baseline Larsen score correlated significantly with anti-CCP, IgM RF, and IgA RF levels, and all measured antibodies correlated with the progression >10 units. The combination of anti-CCP and IgM RF increased the ability to predict @entity74 . CONCLUSION: The data confirmed that measurement of anti-CCP, AKA, APF, and individual isotypes of RFs was useful for prediction of structural damage early in the disease course. Combined analysis of anti-CCP and IgM RF provides the most accurate prediction.

title: Autoantibodies can be prognostic markers of an erosive disease in early XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['erosive and progressive disease']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: INTRODUCTION: @entity907 characterized by @entity551 and @entity1168 . The presence of @entity7129 along with @entity713 during @entity1163 in @entity1 with @entity907 has not been described previously. METHODS AND RESULTS: Two female @entity1 (18 and 16 years old) with recurrent @entity7129 at the time of @entity1163 are described. @entity1 1 had recurrent episodes of @entity1163 . During one of these episodes, which occurred while she was being monitored, @entity7129 along with high-grade @entity713 was seen at the time of @entity1163 and @entity551 . @entity1 2 had a history of recurrent @entity1163 and @entity410 . During one of these episodes, she was documented to have ventricular asystole lasting for about 39 seconds. The sinus rate was 480 msec at the beginning, before slowing down to 960 msec prior to restoration of sinus rhythm with 1:1 AV conduction. The same scenario was repeated during head-up tilt testing. Both @entity1 were treated successfully with oral @entity7306 and, during a follow-up of 28 months and 9 months, have remained symptom-free. CONCLUSION: Sinus acceleration along with high-grade @entity713 during @entity1163 and @entity551 can occur in some @entity1 with @entity907 . The exact mechanism of this phenomenon is unclear.

title: XXXX with @entity713 : an unusual presentation during @entity907 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patient']

entities_list: @entity907 :: ('MESH:D019462', 'Disease') :: ['Neurocardiogenic (vasovagal) syncope is', 'neurocardiogenic syncope']

entities_list: @entity7306 :: ('MESH:D004206', 'Chemical') :: ['disopyramide']

entities_list: @entity7129 :: ('MESH:D013616', 'Disease') :: ['sinus tachycardia', 'syncope and documented sinus tachycardia']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

answer: @entity7129 :: (MESH:D013616,Disease) :: ['Sinus tachycardia']


abstract: BACKGROUND: @entity6800 ( @entity6800 ) is expressed in upper airways, however, little is known regarding whether @entity6800 ( @entity6800 ) signals exert a regulatory effect on the pathogenesis of chronic rhinosinusitis with @entity480 (CRSwNP), especially on @entity32 . We sought to investigate the effect of Poly(IC), the ligand for @entity6800 , on cytokine production by dispersed nasal polyp cells (DNPCs). METHODS: DNPCs were pretreated with or without Poly(IC), and were then cultured in the presence or absence of staphylococcal enterotoxin B (SEB), following which the levels of @entity225 , @entity688 , @entity4047 , @entity4155 and @entity379 in the supernatant were measured. To determine the involvement of @entity688 and cyclooxygenase in Poly(IC)-mediated signaling, DNPCs were treated with anti- @entity688 monoclonal antibody and @entity3522 , the cyclooxygenase inhibitor, respectively. @entity14018 -induced @entity1421 ( @entity1421 ) production was also determined. RESULTS: Exposure to @entity14018 induced a significant production of @entity688 , but not of @entity225 , @entity4047 , @entity4155 or @entity379 by DNPCs. Pretreatment with @entity14018 dose-dependently inhibited SEB-induced @entity225 , @entity4047 and @entity4155 , but not @entity379 production. Neutralization of @entity688 significantly abrogated the inhibitory effect of @entity14018 . Treatment with @entity3522 also abrogated the inhibitory effect of @entity14018 on SEB-induced @entity225 and @entity4047 production. However, unlike exposure of @entity3522 -treated DNPCs to lipopolysaccharide, the ligand for @entity2939 , exposure of these cells to @entity14018 did not enhance @entity225 or @entity4047 production. Poly(IC) did not significantly increase @entity1421 production by DNPCs. CONCLUSIONS: These results suggest that @entity6800 signaling regulates @entity1712 -associated cytokine production in CRSwNP, at least in part, via @entity688 production.

title: Regulatory effect of @entity6800 signaling on staphylococcal enterotoxin-induced @entity225 , @entity4047 , XXXX and @entity379 production in chronic rhinosinusitis with @entity480 .

entities_list: @entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['eosinophilic inflammation']

entities_list: @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2']

entities_list: @entity480 :: ('MESH:D009298', 'Disease') :: ['nasal polyps']

answer: @entity4155 :: (3605,Gene) :: ['IL-17A']


abstract: OBJECTIVE: To investigate the occurrence, genetic inheritance, and @entity393 conditions of @entity8468 ( @entity8468 ), and to measure the width of external aperture of vestibular aqueduct (VA) of @entity8468 , and to analyze the relationship between the @entity393 and the width of external aperture. METHODS: A retrospective review was conducted by the history, auditory, and vestibular function examinations in 95 @entity1 (190 ears) of @entity8468 . The width of VA was measured by CT scanning criterion of each @entity8468 @entity1 in the past 10 years (from 1992 to 2002). RESULTS: In 95 @entity1 , there were male 65 cases and female 30 cases. The male cases was more than the females by a ratio of 2.2:1. Twelve cases (12.6%) would have familial genetic history. The average of the consult age was 7.6 years (range from 1.2 to 39 years). The most @entity1 were misdiagnosed, the @entity393 originated from mild @entity542 in 21 cases (22.1%), the @entity393 after common cold in 13 cases (13.6%). Nine cases (9.5%) misdiagnosed as @entity2459 , 5 cases (5.3%) as @entity2167 @entity393 of @entity4028 antibiotic. The profound @entity393 was found in 172 ears (92.4%). The average width of external aperture of @entity8468 was 7.5 mm +/- 1.2 mm (mean +/- s, 77 cases, 154 ears). The level of @entity393 did not proportional to the width of VA. The @entity393 could be derived from protein-rich endolymph refluxed into the cochlear and vestibule. CONCLUSION: The @entity8468 is distinct clinical entity characterized by fluctuate and progressive SNHL. The diagnosis depends upon the CT scan and MR image. If the hearing fluctuated and subsequently improved, the @entity1 were kept under conservation treatment. If the significantly decreased of hearing effected school performance, the cochlear implant might be considered.

title: [Clinical analysis of 95 @entity1 with XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head trauma']

entities_list: @entity8468 :: ('OMIM:600791', 'Disease') :: ['LVAS', 'large vestibular aqueduct syndrome']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss', 'hearing deterioration', 'hearing impairment']

entities_list: @entity4028 :: ('CHEBI:47779', 'Chemical') :: ['Aminoglycoside']

entities_list: @entity2459 :: ('MESH:D003639', 'Disease') :: ['sudden hearing loss']

answer: @entity8468 :: (OMIM:600791,Disease) :: ['large vestibular aqueduct syndrome']


abstract: UNASSIGNED: Resistance of @entity5 to radiotherapy and/or chemotherapy is one of the important reasons of clinical treatment failure and recurrence. Chemoradiation is an optional method to over-coming of radioresistance and chemoresistance. @entity4259 nanoparticles (SeNPs) with special chemical and physical properties, has been identified as a novel nanocarrier and therapy agent with broad-spectrum anticancer activities due to generate ROS in cells. Herein, X-ray responsive @entity4259 nanoparticles were facilely fabricated by using @entity970 as surface decorator and template. This nanosystem ( @entity970 -SeNPs) demonstrated X-ray responsive property that was attributed to its amorphous characteristic. Interestingly, the nanosystem demonstrated significant radiosensitization effects with X-ray. Specifically, co-treatment of @entity5 cells with @entity970 -SeNPs and X-ray significantly and synergistically enhanced the cells growth inhibition through induction of cell apoptosis, as evidenced by DNA fragmentation and activation of @entity522 . In the cell model, we found that internalized nanoparticles could degrade upon X-ray exposure, which further confirm the X-ray responsive property of the nanoparticles. Moreover, the nanosystem could significantly induced intracellular ROS generation in a time-dependent manner, which peaked at about 40min and gradually decreased thereafter. As a results, ROS overproduction led to mitochondria fragmentation and the cell apoptosis. Taken together, this study provides a novel strategy for rational design and facile synthesis of chemo-radio therapeutic radiosensitization nanomaterials.

title: X-ray-responsive XXXX nanoparticles for enhanced @entity5 chemo-radiotherapy.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity4259 :: ('MESH:D012643', 'Chemical') :: ['Selenium', 'selenium']

answer: @entity4259 :: (MESH:D012643,Chemical) :: ['selenium']


abstract: UNASSIGNED: 7237 Background: The purpose of this study was to determine maximum tolerated dose (MTD) and the dose-limiting @entity137 (DLT) of a combination of @entity136 plus @entity3003 administration in a biweekly schedule for inoperable @entity1149 . METHODS: @entity1 with inoperable stages IIIB and IV @entity1149 included in this study were treated with @entity3003 followed by @entity136 . @entity3003 was given intravenously over 30 minutes, and @entity136 was given intravenously over 30 minutes. RESULTS: Fifteen @entity1 were treated at 4 dose levels. As DLT, treatment delay occurred at dose level 4 in 2 of the 6 @entity1 . No DLT was experienced in dose levels 1, 2, and 3. No other grade 3/4 @entity137 was observed. Twelve @entity1 were available for evaluation of efficacy. Four @entity1 achieved partial response. CONCLUSIONS: MTD was not reached in this study. Considering the treatment continuation, the recommended dose for phase II study is @entity3003 AUC 3 and @entity136 1000mg/m(2) administration every 2 weeks. [Figure: see text] No significant financial relationships to disclose.

title: A phase I study of biweekly combination chemotherapy with @entity136 (GEM) and @entity3003 ( @entity3003 ) for inoperable stages IIIB and XXXX ( @entity1149 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity1149 :: (MESH:D002289,Disease) :: ['IV non-small-cell lung cancer']


abstract: PURPOSE OF REVIEW: To review and evaluate the medical literature on new treatments for periocular infantile (capillary) @entity2695 . Recent studies have shown a promising new therapy for @entity7492 using nonselective b-blockers, including oral @entity1169 and topical @entity6839 . RECENT FINDINGS: Conventional treatments for @entity7492 include the use of @entity288 , laser, surgery, and immunomodulator therapy. Recently, systemic and topical b-blockers have been used to successfully treat @entity7492 . The drugs' mechanism of action remains uncertain, but plausible theories include vasoconstriction, modulation of pro-survival signal transduction pathways, and endothelial cell apoptosis. Whereas no life-threatening adverse events from b-blocker treatment have been described, there have been reports of @entity1168 , @entity551 , @entity5143 , @entity4053 , and electrolyte disturbances resulting from systemic use of @entity1169 to treat @entity7492 . Sleep and @entity344 have also been frequently reported. Topical timolol application for localized, superficial @entity5 may confer similar efficacy as oral @entity1169 while reducing systemic effects. SUMMARY: Despite the recent explosion of interest surrounding this novel treatment, current treatment and protocol-monitoring recommendations are based largely on the experience of individual centers. Several randomized controlled studies are currently underway, the results of which will guide future standard-of-care treatment for @entity7492 .

title: Current concepts in the management of periocular infantile (capillary) XXXX .

entities_list: @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol']

entities_list: @entity7492 :: ('MESH:C535860', 'Disease') :: ['infantile hemangioma']

entities_list: @entity2695 :: ('MESH:D006391', 'Disease') :: ['hemangioma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disturbances']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']

entities_list: @entity5143 :: ('MESH:D001986', 'Disease') :: ['bronchospasm']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity2695 :: (MESH:D006391,Disease) :: ['hemangioma']


abstract: PURPOSE: To date, @entity136 -based or fluoropyrimidine-based regimens are recommended for unresectable advanced @entity1125 . Then, we conducted a phase I study of @entity136 / @entity900 and @entity11730 that is an oral fluoropyrimidine. The aim of this study was to determine the dose-limiting @entity137 (DLT), maximum-tolerated dose, and a recommended phase II dose of @entity11730 . Response was assessed as a secondary endpoint. @entity1 AND METHODS: @entity1 who have been diagnosed with unresectable or postoperative recurrent @entity1125 received @entity900 (25  mg/m(2) i.v. for 120  min) followed by @entity136 (1,000  mg/m(2) i.v. for 30  min) on days 1 and 8, and oral @entity11730 on alternate days; this regimen was repeated at 21-day intervals. A standard '3  +  3' phase I dose-escalation design was adopted. This study was registered with University hospital Medical Information Network (UMIN) Center in Japan, number UMIN000008415. RESULTS: Twelve @entity1 were evaluable in this study. No @entity1 developed DLTs. Recommended dose of @entity11730 was 80 (<1.25  m(2)), 100 (1.25   <=  1.5  m(2)), and 120  mg (1.5  m(2)>= ) per day. One @entity1 could achieve conversion to curative surgery. CONCLUSION: This phase I study was performed safely and demonstrated encouraging response.

title: Phase I trial of @entity11730 every other day in combination with XXXX / @entity900 for inoperable @entity1125 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1125 :: ('MESH:D001661', 'Disease') :: ['biliary tract cancer']

answer: @entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']


abstract: UNASSIGNED: @entity130 ( @entity130 ) describes a regenerative phenomenon in adult @entity1 skin, wherein fully functional hair follicles regenerate de novo in the center of large excisional wounds. Originally described in @entity35 , @entity95 , @entity742 , and @entity1 in 1940-60, the @entity130 phenomenon was reinvestigated in @entity19 only recently. The process of de novo hair regeneration largely duplicates the morphological and signaling features of normal embryonic hair development. Similar to hair development, @entity130 critically depends on the activation of canonical WNT signaling. However, unlike hair development, WNT activation in @entity130 is dependent on @entity13650 signaling generated by the immune system's gamma delta (y  ) T cells. The cellular bases of @entity130 remain to be fully characterized, however, the available evidence leaves open the possibility for a blastema-like mechanism, wherein epidermal and/or dermal wound cells undergo epigenetic reprogramming toward a more plastic, embryonic-like state. De novo hair follicles do not regenerate from preexisting hair-fated bulge stem cells. This suggests that hair neogenesis is not driven by preexisting lineage-restricted progenitors, as is the case for amputation-induced @entity19 digit tip regeneration, but rather may require a blastema-like mechanism. The @entity130 model is characterized by several intriguing features, which await further explanation. These include: (i) minimum wound size requirement for activating neogenesis, (ii) restriction of hair neogenesis to the wound's center, (iii) imperfect patterning outcomes, both in terms of neogenic hair positioning within the wound and in terms of their orientation. Future inquires into the @entity130 process, made possible by a wide array of the available skin-specific genetic tools, will undoubtedly expand our understanding of the regeneration mechanisms in adult mammals.

title: Principles and mechanisms of regeneration in the XXXX model for wound-induced hair follicle neogenesis.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian', 'humans']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['WIHN', 'Wound induced hair follicle neogenesis']

answer: @entity19 :: (10090,Species) :: ['mouse']


abstract: UNASSIGNED: e14626 Background: Unresectable @entity201 is commonly treated with @entity136 -based chemotherapy. Consolidative radiotherapy (RT) is increasingly being used for @entity1 with @entity66 . @entity253 and @entity255 are important causes of morbidity and mortality in @entity201 . The impact of MMT vs. chemotherapy alone on survival and biliary obstruction has not yet been characterized. METHODS: Using the MD Anderson @entity5 registry, we identified 137 @entity1 with @entity201 from 1998-2009 and retrospectively reviewed their records for demographic, epidemiologic, and treatment data. We performed analyses of @entity1349 ( @entity1349 ) using the Kaplan-Meier method with stratification by extent of disease (locally advanced vs. metastatic). We used the Pearson chi-square test to analyze the impact of RT on measures of disease-related morbidity. RESULTS: The median @entity1349 of the entire group was 48 weeks. 64% of @entity1 had locally advanced disease and 71% received at least one line of therapy. @entity1 receiving first-line @entity136 plus @entity900 (n=42) had a superior @entity1349 when compared to those receiving other first-line therapies (n=55; 71 weeks vs. 50 weeks, p=0.02). There was no significant improvement in @entity1349 in those @entity1 who received RT (n=48) vs. those who never received RT (n=49; 58 weeks vs. 54 weeks, p=0.96). However, @entity1349 with consolidative RT (n=13) was 113 weeks vs. 70 weeks with chemotherapy alone (n=29) [p=0.11]. RT did not significantly reduce the morbidity of @entity201 , including non-elective biliary stent exchanges (p=0.79), admissions for obstructive @entity1087 or @entity255 (p=0.57), and non-elective, cancer-related admissions (p=0.69). CONCLUSIONS: This series of @entity201 @entity1 confirms the previously reported survival improvement with @entity136 plus @entity900 in the first-line setting for bile duct @entity5 . The role of RT in reducing biliary complications from @entity201 remains unclear. Consolidative RT may increase survival in selected @entity1 compared to chemotherapy alone, although this requires further investigation in prospective, randomized clinical trials.

title: The role of multimodality therapy (MMT) in XXXX ( @entity201 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['localized disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity201 :: ('MESH:D018281', 'Disease') :: ['UHC', 'hilar cholangiocarcinoma']

entities_list: @entity253 :: ('MESH:D001660', 'Disease') :: ['Biliary obstruction']

entities_list: @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity201 :: (MESH:D018281,Disease) :: ['unresectable hilar cholangiocarcinoma']


abstract: OBJECTIVE: To explore the expression of caveolin-1 ( @entity3895 -1) induced by interleukin-17F/IL-17 receptor C ( @entity4654 / @entity13771 ) in @entity35 pulmonary microvascular endothelial cells (PMVECs). METHODS: Cultured PMVECs were divided into two groups of time-dependent experiment and @entity13771 signal pathway intervention according to the results of time-dependent experimental group: namely peak time of @entity4654 -induced @entity3895 -1 and its phosphorylation (p- @entity3895 -1) expression of PMVEC for formulating the incubation time between @entity4654 and PMVEC in @entity13771 signal pathway intervention group. Time-dependent experiment group: Western blot was used to detect the expression of @entity3895 -1 after @entity4654 stimulation for 0, 0.5, 1.5, 3.0, 6.0, 12.0, 24.0 h. @entity3895 -1 and its phosphorylation expression after @entity4654 challenge for 0, 10, 30, 60, 90, 120 min were evaluated by Western blot. @entity13771 signal pathway intervention group: PMVECs were divided into two groups after a 3-day pre-treatment of siRNA. The first group received a 60-min stimulation of 100 ng/ml @entity4654 before detecting the expression of p- @entity3895 -1 while the second group was subject to a 24-hour stimulation of 100 ng/ml @entity4654 before detection. In addition, control, meaningless-siRNA, @entity13771 -siRNA, @entity4654 and meaningless-siRNA + @entity4654 groups were set as references for two groups respectively. RESULTS: @entity4654 up-regulated the expression of @entity3895 -1 in a time-dependent manner. At 0, 0.5, 1.5, 3.0, 6.0, 12.0, 24.0 h, the relative expression levels of @entity3895 -1 were (1.139    0.134), (1.276    0.166), (1.604    0.080), (2.115    0.231), (2.763    0.226), (3.309    0.493) and (3.963    0.169). At 1.5 h, it was significantly higher than 0 h, peaked at 24.0 h and remained significantly higher than 0, 0.5, 1.5, 3.0, 6.0, 12.0 h (all P < 0.05). And @entity4654 increased the expression of p- @entity3895 -1 in a time-dependent manner. At 0, 10, 30, 60, 90, 120 min, the relative expression levels of p- @entity3895 -1 were (0.540    0.085), (0.880    0.084), (1.437    0.297), (1.491    0.212), (1.017    0.210) and (0.882    0.074). At 10 min, p- @entity3895 -1 was significantly higher than 0 min, peaked at 60 min, remained significantly higher than 0, 10, 30, 90, 120 min (all P < 0.05) and gradually decreased. At 120 min, it was still higher than 0 min. Compared with @entity4654 group, @entity13771 -siRNA significantly inhibited @entity4654 -induced @entity3895 -1 and its phosphorylation (2.126    0.318 vs 3.897    0.424 and 1.014    0.136 vs 1.431    0.298, all P < 0.05). CONCLUSIONS: @entity4654 up-regulates the expressions of @entity3895 -1 and p- @entity3895 -1 in a time-dependent manner in PMVECs. And the silenced expression of @entity13771 in PMVECs by @entity13771 -siRNA significantly inhibits the @entity4654 -induced expressions of @entity3895 -1 and p- @entity3895 -1.

title: [Effects of IL-17F/IL-17RC on the expression of caveolae-1 in XXXX pulmonary microvascular endothelial cells].

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: AIM: To explore whether it is possible to predict a @entity1 's eventual @entity6 phenotype using characteristics at initial presentation, we reassessed 111 young @entity1 on average 7.8    4.2 (2.2-19.7) [mean    SD (range)] years after diagnosis. METHODS: Medical records at diagnosis for 111 @entity1 , aged 0-17, were compared with their follow-up characteristics including stimulated @entity2690 (CP) and islet @entity2621 ( @entity2621 ). RESULTS: Initially, 18 @entity1 were @entity28 ; 9 displayed other @entity2175 (T2DM) features ( @entity3610 , @entity3594 , diagnosed T2DM); the remaining 84 had a classic type 1 @entity6 (T1DM) presentation. At follow-up, 83 @entity1 (75%) with no measured CP were classified as T1DM; 17 (15%) were CP+ and @entity2621 - and thus considered T2DM. Eleven @entity1 with both T1DM and T2DM features were classified as having mixed @entity6 phenotype ( @entity709 ). One-fifth (22 subjects) changed presumed phenotype at follow-up. In multivariable models, T1DM @entity1 were younger at diagnosis, had higher initial @entity413 values, were more likely to have experienced @entity1270 , and less likely to be @entity28 or of African American ethnicity. CONCLUSIONS/INTERPRETATION: Ten percent of subjects had @entity709 and 15% had T2DM at    8 years' duration. Although no onset feature was completely reliable, @entity1270 and @entity4854 were more likely to predict T1DM; @entity28 and African American ethnicity made T2DM more likely. At diagnosis, features of T2DM in addition to @entity28 were strongly predictive of eventual T2DM phenotype. Given the significant percentage who changed or had mixed phenotype, careful tracking of all young @entity1 with @entity6 is essential to correctly determine eventual disease type.

title: Onset features and subsequent clinical evolution of childhood XXXX over several years.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'people', 'child']

entities_list: @entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes']

entities_list: @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'obesity']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity2621 :: ('MESH:D050031', 'Disease') :: ['autoantibodies', 'AB']

entities_list: @entity3594 :: ('MESH:D000052', 'Disease') :: ['acanthosis']

entities_list: @entity1270 :: ('MESH:D007662', 'Disease') :: ['ketoacidosis']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: @entity1317 during @entity572 ( @entity572 ) are rare but when they occur, have serious consequences. These have traditionally been managed with open exploration and repair, but more recently there has been a trend towards percutaneous endovascular management. We performed a systematic review of the literature to assess if this change in trend has led to an improvement in the overall reported rates of morbidity and mortality during the last 22 years in comparison with the reviews of the literature published previously. We found a total of 61 articles describing 138 @entity1317 in 124 @entity1 . Injuries because of a laceration were the most prevalent (n = 51, 44%) and the most common presenting feature, when recorded, was @entity548 (n = 41, 53.3%). Delay in diagnosis was associated with the type of @entity455 (p < 0.001) and the clinical presentation (p  =  0.002). Open exploration and repair was the most common form of management, however percutaneous endovascular intervention was used in one third of the injuries and more constantly during the last 13 years. The main overall reported complications included @entity204 (n = 9, 7.3%), amputation (n = 2, 1.6%), and persistent ischaemia (n = 9, 7.3%). When compared with previous reviews there was a similar rate of mortality but lower rates of amputation and @entity2319 , especially in @entity1 managed by endovascular strategies. Cite this article: Bone Joint J 2015;97-B:1447-55.

title: XXXX during arthroplasty of the hip.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular lesion']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity2319 :: ('MESH:D003638', 'Disease') :: ['permanent disability']

entities_list: @entity572 :: ('MESH:D006617', 'Disease') :: ['THA', 'total hip arthroplasty']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['vascular injuries', 'Vascular injuries']

answer: @entity1317 :: (MESH:D057772,Disease) :: ['Iatrogenic vascular injuries']


abstract: BACKGROUND: @entity1 with @entity157 ( @entity157 ) beyond the Milan criteria are expected to have inferior outcome after liver transplantation (LT) and are therefore currently not considered for LT in many countries. The purpose of this study was to identify predictive factors for overall survival following LT for @entity157 that may support the Milan criteria in the selection of appropriate transplant candidates. METHODS: Clinicopathological data on 364 @entity1 with @entity157 who underwent LT between 1989 and 2010 were retrospectively evaluated. Predictors of overall survival in the entire cohort as well as in subsets of @entity1 within (n = 214) and beyond (n = 150) the Milan criteria were analyzed. RESULTS: Multivariate analysis in the entire cohort identified DNA index >1.5 (p < 0.0001), @entity160 ( @entity160 ) >200 ng/ml (p = 0.005), and @entity157 beyond the Milan criteria (p = 0.002) to be associated with worse overall survival. In @entity1 within the Milan criteria (median survival: 170 months), DNA index >1.5 (p < 0.0001) was the only predictor of worse overall survival in multivariate analysis. In @entity1 beyond the Milan criteria (median survival: 44 months), DNA index >1.5, @entity160 >200 ng/ml, microvascular invasion, @entity1 age >60 years, and DNA index >1.5 concomitant with @entity160 >200 ng/ml were associated with worse overall survival in univariate analysis. Multivariate analysis identified DNA index >1.5 concomitant with @entity160 >200 ng/ml (p < 0.0001) as the only independent predictor of worse overall survival. Consequently, @entity1 beyond the Milan criteria with a combined favorable DNA index  <=1.5 and @entity160  <=200 ng/ml had a median survival (147 months) comparable to that of @entity1 within the Milan criteria. CONCLUSIONS: DNA index and @entity160 level predict overall survival following LT in @entity1 with advanced @entity157 beyond the Milan criteria. A combined assessment of these markers during the evaluation of transplant candidates can contribute to the selection of @entity1 with @entity157 who may benefit from LT independently of their @entity5 burden.

title: XXXX DNA Index and @entity160 Define Outcome following Liver Transplantation for Advanced @entity157 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity160 :: ('174', 'Gene') :: ['AFP', 'a-fetoprotein level']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Tumor']


abstract: OBJECTIVE: @entity1211 ( @entity1211 ) is associated with almost 300,000 @entity204 per year in the United States. Novel oral anticoagulants (NOACs) offer an alternative to @entity1229 -based therapy without monitoring requirements and with fewer drug and food interactions. @entity14242 , a direct Xa inhibitor, is approved by the Food and Drug Administration (FDA), based upon results of the Hokusai- @entity1211 Phase 3 trial. The trial demonstrated that @entity14242 administered once daily after initial treatment with heparin was non-inferior in reducing the risk of @entity1211 recurrence and caused significantly less major and clinically relevant non-major (CRNM) bleeding compared to @entity1229 . The objective of this study was to evaluate the cost-effectiveness of @entity14242 versus @entity1229 for the treatment of adults with @entity1211 . METHODS: A cost-effectiveness model was developed using @entity1 -level data from the Hokusai- @entity1211 trial, clinical event costs from real-world databases, and drug acquisition costs for @entity1229 of  0.36 and @entity14242 of  9.24 per tablet. RESULTS: From a U.S. health-care delivery system perspective, the incremental cost-effectiveness ratio (ICER) was  22,057 per quality adjusted life year (QALY) gained. Probabilistic sensitivity analysis showed that @entity14242 had an ICER < 50,000 per QALY gained relative to @entity1229 in 67% of model simulations. The result was robust to variation in key model parameters including the cost and disutility of @entity1229 monitoring. CONCLUSION: Despite its higher drug acquisition cost, @entity14242 is a cost-effective alternative to @entity1229 for the treatment of @entity1211 .

title: Cost-effectiveness of XXXX for the treatment of @entity1211 based on the Hokusai- @entity1211 study.

entities_list: @entity14242 :: ('MESH:C552171', 'Chemical') :: ['edoxaban', 'Edoxaban']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['Venous thromboembolism', 'VTE']

entities_list: @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']

answer: @entity14242 :: (MESH:C552171,Chemical) :: ['edoxaban']


abstract: INTRODUCTION: @entity2460 of the pleura (SFTP) are @entity5 arising from mesenchymal cells. Immunohistochemical studies have demonstrated that the origin of these @entity5 is mesenchymal rather than mesothelial. The aim of this study is to present our experience with diagnosing and treating @entity1 with SFTP. MATERIAL AND METHODS: We analyzed 18 @entity1 treated at the Department of Thoracic Surgery of the Medical University of Lodz. The @entity1 ' medical histories and the results of postoperative histopathological investigation of the @entity5 were analyzed. Postoperative histopathological samples were evaluated with regard to the current criteria of @entity5 . RESULTS: In 17 @entity1 , the @entity5 were surgically removed. Benign and small lesions (less than 3 cm in size) were removed by video-assisted thoracoscopic surgery (VATS). In 5 cases, @entity5 were found in the postoperative material. CONCLUSIONS: @entity2460 of the pleura is a @entity5 with frequently asymptomatic clinical course. Treatment consists in resection which includes the adjacent structures, especially if the @entity5 is malignant.

title: XXXX of the pleura - analysis of 18 cases.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'malignant tumors', 'malignancy', 'tumors']

entities_list: @entity2460 :: ('MESH:D054364', 'Disease') :: ['Solitary fibrous tumors']

answer: @entity2460 :: (MESH:D054364,Disease) :: ['Solitary fibrous tumor']


abstract: The mechanisms of progression from @entity1560 to @entity1560 and @entity82 are not well elucidated. Hepatocellular apoptosis could be one of the key factors in the pathogenesis of @entity7936 ( @entity7936 ). @entity99 ( @entity99 ) protects liver cells from various toxins. We previously reported that @entity99 is critically important for the survival of hepatocytes due to its mitochondrial association. This study aims to investigate the relationship between @entity99 and hepatocellular apoptosis in vivo models of high-fat diet-induced @entity7936 and in vitro models of @entity7609 -induced @entity130 . @entity35 were fed a high-fat diet for 8, 12 and 16  weeks. Hepatic histological lesions, liver function and apoptosis were examined. @entity99 expression, in association with @entity4124 and cytochrome c leakage, which are both indicators of cell apoptosis, was measured. Results showed that a high-fat diet altered liver function and histology in a manner resembling @entity7936 . Hepatic protein and mRNA @entity99 expression was decreased as @entity7936 progressed. Meanwhile, cell apoptosis increased as result of @entity4124 activation and cytochrome c release, indicating that @entity99 might be involved in @entity7936 pathogenesis. Furthermore, in @entity7609 -induced @entity99 , over-expression of @entity99 decreased cells apoptosis. In contrast, repression of @entity99 expression by siRNA increased cell apoptosis. In conclusion, these data imply that cell apoptosis contributes to the pathogenesis of @entity7936 , during which @entity99 expression is downregulated. Increasing @entity99 expression in hepatocytes may forestall cell apoptosis as result of @entity844 insult.

title: Increased hepatic apoptosis in high-fat diet-induced @entity7936 in XXXX may be associated with downregulation of hepatic stimulator substance.

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity1560 :: ('MESH:D005234', 'Disease') :: ['fatty liver', 'steatohepatitis']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['hepatocyte injury']

entities_list: @entity7936 :: ('MESH:D005235', 'Disease') :: ['NASH', 'non-alcoholic steatohepatitis']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['Hepatic stimulator substance', 'hepatic cell damage', 'HSS']

entities_list: @entity7609 :: ('MESH:D019308', 'Chemical') :: ['palmitic acid']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: BACKGROUND: Most @entity683 vaccines are manufactured in eggs, and the inactivated virus is purified for injection. For a seasonal @entity683 product, manufacturing, distribution, and perhaps even vaccine coverage, would be greatly improved with an oral tablet alternative made in cell culture. We aimed to assess the safety and immunogenicity of an oral tablet vaccine against @entity683 A H1N1 in healthy adults. METHODS: At a single site, we did a randomised, double-blind, placebo-controlled trial of a monovalent @entity683 A H1N1 vaccine to establish the safety and immunogenicity of a recombinant, non-replicating, adenovirus vector expressing haemagglutinin and double-stranded RNA adjuvant delivered orally by tablets. @entity1 had to have an initial haemagglutination inhibition titre of at @entity30333 , be aged between 18 and 49 years, and be in good health. We randomly assigned (1:1) @entity1 to receive either a single oral dose of vaccine or placebo. Randomisation was done by computer-generated assignment, and study drug was distributed with concealed identity to the masked staff by an unmasked pharmacist. Investigative site staff, @entity1 directly involved with immunological assays or the assessment of clinical safety, and @entity1 were masked to treatment assignments. Solicited symptoms of reactogenicity were assessed, and all safety assessments were reported through the active phase of the study (day 28). Immunogenicity was assessed by haemagglutination inhibition titres, the percentage of @entity1 that seroconverted, microneutralisation titres, and the number of antibody secreting cells. Descriptive statistics were used for continuous variables and t-tests or Fisher's exact tests were used to compare treatment groups. The study is registered at ClinicalTrials.gov, number NCT01688297. FINDINGS: 24 @entity1 were enrolled in the study at WCCT Global between Dec 2, 2013, and April 15, 2014. Adverse events were mild in nature, and occurred with similar frequency in vaccine (four events) and placebo recipients (four events). After immunisation, 11 (92%) of 12 vaccine-treated @entity1 had a four-fold increase in haemagglutination inhibition titres (group geometric mean fold rise of 7  7) and microneutralisation titres (group geometric mean fold rise of 29). No @entity1 in the placebo group had a four-fold increase in haemagglutination inhibition titres (group geometric mean fold rise of 1  1) or microneutralisation titres (group geometric mean fold rise of 1  0). Neutralising antibody responses to @entity683 were not hindered by pre-existing immunity to the vector. INTERPRETATION: An oral recombinant adenovirus vaccine to @entity683 was well tolerated and can elicit neutralising antibody responses to @entity683 virus in @entity1 beings. These data are a step forward in making oral @entity683 vaccination possible. FUNDING: Vaxart Inc.

title: High titre neutralising antibodies to XXXX after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'human', 'Participants', 'people']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['influenza']

answer: @entity683 :: (MESH:D007251,Disease) :: ['influenza']


abstract: @entity14341 is a triggering agent for reactive @entity625 in HLA-B27-susceptible individuals. Considering the intracellular multiplication of bacteria, it seems likely that bacterial peptides may be presented by the major histocompatibility complex (MHC) class I pathway. To examine this hypothesis, we infected @entity1530 *2705- and/or @entity1 @entity2262 -transfected @entity19 L-cell lines with @entity45041 , an invasive strain of @entity14341 . @entity2348 induced no detectable modifications in the biosynthesis and expression level of HLA-B27, as assessed by immunoprecipitation, Northern blot analysis, and flow cytometry. Using confocal microscopy, we observed that @entity2348 induced a clustering of HLA-B27 molecules during macropinocytosis and before bacterial dissemination from cell to cell. Peptides naturally bound to HLA-B27 molecules were acid eluted from infected cells and separated by high-performance liquid chromatography. Major differences were observed in high-performance liquid chromatography profiles and in the nature of peptides presented following @entity2348 . Although most of the antigens presented were not accessed by Edman degradation, we obtained two sequences partially homologous to bacterial proteins. These peptides lacked the major HLA-B27 peptide anchor ( @entity534 ) at position 2, and one had an unusual length of 14 @entity1522 . These data suggest that alterations in the peptide presentation by HLA-B27 occur during @entity281 , which could be relevant to the pathogenesis of HLA-B27-related @entity625 .

title: Alteration of HLA-B27 peptide presentation after XXXX of transfected @entity19 L cells by @entity14341 .

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity2262 :: ('567', 'Gene') :: ['beta2-microglobulin']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infection', 'Bacterial infection']

entities_list: @entity45041 :: ('p|SUB|M|90|T', 'ProteinMutation') :: ['M90T']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity14341 :: ('623', 'Species') :: ['Shigella flexneri', 'S. flexneri']

answer: @entity281 :: (MESH:D007239,Disease) :: ['infection']


abstract: The role of the cerebellum in the spatial tuning of goal-directed multi-joint movements in @entity1 is unknown. We analyzed the directional tuning of phasic EMG activities associated with upper limb reaching movements (12 targets) in the vertical plane in healthy subjects and in @entity1 exhibiting @entity6447 . Tuning of phasic EMG activities was investigated in seven muscles (brachioradialis, biceps, medial and long head of triceps, anterior and posterior deltoid, latissimus dorsi). We digitally compressed the EMG activities corresponding to slow reaches to the same targets into the time frame of the fast EMG traces. Estimates of gravity-related components were subtracted. Peaks of EMG activities in the resulting phasic traces were identified for each muscle and each target. Aberrant privileged directions of M Peak EMG (directions associated with the maximal peak of EMG amongst the 12 peaks of EMG activity in the sagittal plane) were found in all @entity2055 @entity1 . Directional dominance, defined as the ratio of the M Peak EMG divided by the peak EMG in the opposite direction, was significantly higher in controls than in @entity2055 @entity1 for one distal muscle (brachioradialis) and one proximal muscle (anterior deltoid). The spreading of EMG activities assessed by the global areas of the polar plots of phasic traces was broader in @entity1 for the biceps and medial head of triceps. The distribution of densities of EMG activities (DDEMG) amongst the four quarters of the vertical plane, an index of the contrast in the intensities between quarters in polar plots, revealed increased values in control subjects for the brachioradialis, the biceps and the anterior deltoid as compared to @entity2055 @entity1 . Representation of Net Vectors obtained from polar plots of peaks of EMG activities demonstrated an abnormal directional tuning in @entity2055 @entity1 . In the majority of the cases, the Net Vector was outside the normal range for the following muscles: brachioradialis, biceps, anterior deltoid, posterior deltoid. This study reveals that @entity6447 is associated with defective spatial properties of EMG activity during multiple joint movements. Privileged directions associated with M Peak EMG and Net Vectors are erroneous. We demonstrate that the cerebellum plays a determinant and unsuspected role in the spatial modulation of activation during speed-related action for reaching.

title: Directional tuning of speed-related activation for reaching in the vertical plane in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity6447 :: ('MESH:D002524', 'Disease') :: ['cerebellar ataxia']

answer: @entity6447 :: (MESH:D002524,Disease) :: ['cerebellar ataxia']


abstract: @entity4536 is a common @entity4002 world-wide but not in Central Europe. The typical clinical manifestation is an enlarging papule on the site of @entity281 . Vectors are sandflies and reservoirs may be wild animals like rodents, @entity235 or even @entity1 . @entity1 with any kind of @entity465 are at risk. We report on two otherwise healthy @entity1 , 16 and 18 years-of-age, who presented non-healing @entity922 . The diagnosis of @entity4536 was confirmed through intracellular amastigotes in Giemsa stains of skin biopsies. One @entity281 was of Syrian origin and the other was contracted in Tuscany. Since both lesions were classified as complex cutaneous lesions, drug therapy was initiated with @entity2059 orally or intralesional @entity1559 antimonite. A complete response was obtained in both @entity1 . No other adverse effects rather than injection pain with @entity1559 antimonite were observed. We should be aware of @entity4536 in travelers returning from endemic regions or from migrants and refugees from endemic regions.

title: Non-healing XXXX : cutaneous old world leishmaniasis in dresden.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'humans', 'patients']

entities_list: @entity4002 :: ('MESH:D011778', 'Disease') :: ['vector-borne disease']

entities_list: @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']

entities_list: @entity1559 :: ('MESH:D008536', 'Chemical') :: ['meglumine']

entities_list: @entity465 :: ('MESH:D007153', 'Disease') :: ['immunodeficiency']

entities_list: @entity4536 :: ('MESH:D016773', 'Disease') :: ['cutaneous leishmaniasis', 'Cutaneous leishmaniasis']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['facial lesions']

answer: @entity922 :: (MESH:D013568,Disease) :: ['facial lesions']


abstract: BACKGROUND: Meat protein digestibility can be impaired because of indigestible protein aggregates that form during cooking. When the aggregates are subsequently fermented by the microbiota, they can generate potentially harmful compounds for the @entity694 . OBJECTIVE: This study evaluated the quantity of @entity291 meat protein escaping digestion in the @entity1 small intestine and the metabolic fate of exogenous @entity1568 , depending on cooking processes. METHODS: Sixteen volunteers (5 @entity1 and 11 @entity1 ; aged 28    8 y) were equipped with a double lumen intestinal tube positioned at the ileal level. They received a test meal exclusively composed of 120 g of intrinsically @entity13140 -labeled @entity291 meat, cooked either at 55  C for 5 min (n = 8) or at 90  C for 30 min (n = 8). Ileal effluents and blood and urine samples were collected over an 8-h period after the meal ingestion, and @entity13140 enrichments were measured to assess the digestibility of meat proteins and the transfer of dietary @entity1568 into the metabolic pools. RESULTS: Proteins tended to be less digestible for the meat cooked at 90  C for 30 min than at 55  C for 5 min (90.1%    2.1% vs. 94.1%    0.7% of ingested N; P = 0.08). However, the particle number and size in ileal digesta did not differ between groups. The appearance of variable amounts of intact fibers was observed by microscopy. The kinetics of @entity13140 appearance in plasma proteins, @entity3534 , and @entity1133 were similar between groups. The amount of exogenous @entity1568 lost through deamination did not differ between groups (21.2%    0.8% of ingested N). CONCLUSIONS: Cooking @entity291 meat at a high temperature for a long time can moderately decrease protein digestibility compared with cooking at a lower temperature for a short time and does not affect postprandial exogenous protein metabolism in young adults. The study was registered at www.clinicaltrials.gov as NCT01685307.

title: High True Ileal Digestibility but Not Postprandial Utilization of XXXX from @entity291 Meat Protein in @entity1 Is Moderately Decreased by High-Temperature, Long-Duration Cooking.

entities_list: @entity3534 :: ('MESH:D000596', 'Chemical') :: ['amino acids']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic mucosa']

answer: @entity1568 :: (MESH:D009584,Chemical) :: ['Nitrogen']


abstract: OBJECTIVE: To investigate the cutaneous safety and tolerability of @entity10758 1.2%/ @entity18575 3.75% gel in moderate-to-severe @entity5477 @entity1 . METHODS: A safety assessment of 498 @entity1 with moderate-to-severe @entity5477 receiving @entity10758 1.2%/ @entity18575 3.75% gel or vehicle for 12 weeks. RESULTS: The vast majority (80-95%) of @entity1 reported no cutaneous safety or tolerability problems throughout the study. Mean scores for both active and vehicle were all <1 (where l=mild) and reduced over the duration of the study. When scaling, @entity5105 , itching, burning, or stinging was reported it was generally mild. Moderate or severe reactions to @entity10758 1.2%/ @entity18575 3.75% gel were rare and generally seen early in treatment. There were eight reports (3.3%) of moderate @entity5105 , four reports (1.7%) of moderate scaling, three reports (1.2%) of moderate itching, and one report of moderate burning (0.4%) at Week 4. There was one report (0.4%) of severe @entity5105 and one report (0.4%) of severe burning (both at Week 4), with one report (0.4%) of severe stinging at Week 12. There were no substantive differences seen in cutaneous tolerability among treatment groups and younger @entity1 tended to have milder reactions. LIMITATIONS: It is not possible to determine the contributions of the individual active ingredients. CONCLUSION: @entity10758 1.2%/ @entity18575 3.75% gel has a favorable safety and tolerability profile with very low incidence of moderate or severe reactions.

title: Cutaneous Safety and Tolerability of a Fixed Combination Clindamycin (1.2%) and @entity18575 (3.75%) Aqueous Gel in Moderate-to-severe XXXX .

entities_list: @entity10758 :: ('MESH:C007084', 'Chemical') :: ['clindamycin phosphate', 'Clindamycin phosphate']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity18575 :: ('MESH:D001585', 'Chemical') :: ['benzoyl peroxide']

answer: @entity5477 :: (MESH:D000152,Disease) :: ['Acne Vulgaris']


abstract: We evaluated the efficacy and safety of three concentrations of @entity1343 infused epidurally as @entity1337 for @entity1 undergoing orthopedic procedures. @entity1 undergoing elective hip or knee joint replacement were enrolled in the study (n = 105). Sensory blockade was established preoperatively with 10-15 mL of 0.75% @entity1343 . @entity1 were then randomized to receive 0.0625%, 0.125%, or 0.25% @entity1343 as a continuous epidural infusion at 6 mL/h for 24 h. IV @entity1286 @entity1 -controlled @entity1337 was given as rescue @entity1337 , and time to first request for @entity1337 and total dose of @entity1286 consumed were recorded. Sensory blockade, motor blockade, visual analog scale @entity158 score, and cardiovascular variables were also recorded at regular intervals postoperatively. Ninety-one @entity1 were included in the primary intent-to-treat analysis. Total normalized dose of @entity1286 , number of @entity1 -controlled @entity1337 requests, and overall postoperative visual analog scale @entity158 scores were significantly lower for the 0.25% group compared with the other two groups, and the time to first request for rescue @entity1337 was longer. There was no significant difference between the 0.125% and 0.25% groups in terms of maximum motor blockade achieved and time to minimal motor blockade. Safety data were equivalent among the three groups. We conclude that @entity1343 as a continuous epidural infusion provided adequate postoperative @entity1337 and that the 0.25% concentration provided significantly longer @entity1337 than 0.125% or 0.0625% @entity1343 without any significant increase in detectable motor blockade relative to the 0.125% group. IMPLICATIONS: Postoperative epidural infusion of @entity1343 can provide safe and effective @entity1337 for @entity1 having hip or knee joint replacement. Of the three concentrations we infused at a constant rate, 0.25% provided significantly better @entity158 relief.

title: The efficacy and safety of three concentrations of XXXX administered as a continuous epidural infusion in @entity1 undergoing orthopedic surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity1343 :: ('MESH:C476513', 'Chemical') :: ['levobupivacaine']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine']

answer: @entity1343 :: (MESH:C476513,Chemical) :: ['levobupivacaine']


abstract: Delivery of neurotrophic molecules to the brain has potential for preventing @entity528 in @entity179 . @entity2846 ( @entity2846 ) epithelial cells secrete numerous neurotrophic factors, and encapsulated @entity2846 transplants are neuroprotective in models of @entity64 and @entity2033 ( @entity2033 ). To date, all studies examining the neuroprotective potential of @entity2846 transplants have used cells isolated from young donor animals. Because the aging process significantly impacts the cytoarchitecture and function of the @entity2846 the following studies determined whether age-related impairments occur in its neuroprotective capacity. @entity2846 was isolated from either young (3-4 months) or aged (24 months) @entity35 . In vitro, young @entity2846 epithelial cells secreted more @entity6667 and were metabolically more active than aged @entity2846 epithelial cells. Additionally, conditioned medium from cultured aged @entity2846 was less potent than young @entity2846 at enhancing the survival of serum-deprived neurons. Finally, encapsulated @entity2846 was tested in an animal model of @entity2033 . Cell-loaded or empty alginate capsules (control group) were transplanted unilaterally into the @entity35 striatum. Seven days later, the animals received an injection of @entity8113 (QA; 225 nmol) adjacent to the implant site. Animals were tested for motor function 28 days later. In the control group, @entity75 severely impaired function of the contralateral forelimb. Implants of young @entity2846 were potently neuroprotective as @entity35 receiving @entity2846 transplants were not significantly impaired when tested for motor function. In contrast, implants of @entity2846 from aged @entity35 were only modestly effective and were much less potent than young @entity2846 transplants. These data are the first to directly link aging with diminished neuroprotective capacity of @entity2846 epithelial cells.

title: Aging reduces the neuroprotective capacity, XXXX secretion, and metabolic activity of @entity35 choroid plexus epithelial cells.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['QA lesions']

entities_list: @entity2033 :: ('MESH:D006816', 'Disease') :: ["Huntington's disease", 'HD']

entities_list: @entity8113 :: ('MESH:D017378', 'Chemical') :: ['quinolinic acid']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disorders']

entities_list: @entity2846 :: ('MESH:D020288', 'Disease') :: ['CP', 'Choroid plexus']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal loss']

answer: @entity6667 :: (83785(Tax:10116),Gene) :: ['VEGF']


abstract: STUDY OBJECTIVES: To evaluate the histocompatibility of four different materials used to cover expandable metallic stents. DESIGN: Prospective, randomized, unblinded study. SETTING: Animal research laboratory of Kurume University. @entity1 OR @entity1 : Twenty 12- to 18-kg mongrel @entity235 . INTERVENTIONS: Handmade Gianturco-type stents with six bends, 20 mm in length, and 15 to 20 mm in diameter were covered using four different materials: @entity7502 mesh, @entity1346 -coated mesh, @entity2635 mesh, and ePTFE. Covered stents were inserted into the @entity825 after i.v. anesthesia. Five animals were used in each group. MEASUREMENTS AND RESULTS: Postinsertion status was observed using clinical and bronchoscopy measures 7, 14, 28, and 56 days after intervention. Eight weeks after stent insertion, the tracheal specimens were studied pathologically. A scoring system was used to evaluate the histocompatibility of covered stents in each study group. The mean of clinical scores in the @entity7502 group was 1.84+/-0.36, which was significantly higher than those in the groups of @entity1346 , @entity2635 , and ePTFE. The means of histopathologic scores in the @entity7502 group and the @entity1346 group were 1.60+/-0.55, which were significantly higher than those in groups of @entity2635 and ePTFE. CONCLUSIONS: @entity7502 mesh cover was more suitable than @entity1346 -coated mesh, @entity2635 mesh, and ePTFE because of its excellent histocompatibility.

title: Experimental study of the histocompatibility of covered expandable metallic stents in the XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['PATIENTS', 'PARTICIPANTS']

entities_list: @entity7502 :: ('MESH:D011126', 'Chemical') :: ['Polypropylene', 'polypropylene']

entities_list: @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone']

entities_list: @entity2635 :: ('CHEBI:60160', 'Chemical') :: ['polyester']

answer: @entity825 :: (MESH:D055090,Disease) :: ['trachea']


abstract: OBJECTIVE AND IMPORTANCE: Chronic encapsulated @entity1779 is a fairly rare clinical entity. This unique lesion is peculiar for its clinical onset, formation of a capsule, and progressive enlargement. The mechanism for capsule formation and self-perpetuating expansion still remains uncertain, as well as the causal relationship with @entity1462 . Because of their pseudotumoral course and misleading neuroradiological features, these lesions can be misdiagnosed preoperatively as @entity1313 . CLINICAL PRESENTATIONS: A 62-year-old @entity1 was referred with a 2-month history of generalized @entity410 . There was no history of @entity542 or arterial @entity101 . The results of a neurological examination were normal. Computed tomographic scans revealed a slightly hyperdense roundish area in the right parietotemporal region with ring-like enhancement after contrast medium injection, moderate mass effect, and perifocal low attenuation. With the provisional diagnosis of @entity816 , the @entity1 was admitted for a craniotomy. Before surgery, a thallium-201 single photon emission computed tomographic study was performed, which showed no abnormal uptake of the tracer, raising significant doubt regarding the presumptive diagnosis of a @entity5 . INTERVENTION: Intraoperative findings revealed a @entity1410 , with a well-demarcated, thick, fibrous-elastic capsule. There was evidence of repeated intracapsular @entity548 . The lesion was totally removed, and the @entity1 recovered fully. No other pathological findings, including @entity1462 , were noted. CONCLUSION: Chronic encapsulated intracerebral @entity1410 probably occur more frequently than the limited number of reported cases would indicate. This case represents a realistic clinical problem-solving setting in with @entity4214 -201 single photon emission computed tomography was used because of its capacity for functional @entity5 detection and differential diagnosis.

title: Chronic encapsulated XXXX : contribution of thallium-201 single photon emission computed tomography in preoperative diagnosis: case report.

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['tonicoclonic seizures']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhages']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['cerebral neoplasms']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head injury']

entities_list: @entity4214 :: ('MESH:D013793', 'Chemical') :: ['thallium']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas', 'hematoma']

entities_list: @entity816 :: ('MESH:D001254', 'Disease') :: ['astrocytoma']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hematoma']

entities_list: @entity1462 :: ('MESH:D054079', 'Disease') :: ['vascular malformations']

answer: @entity1779 :: (MESH:D002543,Disease) :: ['intracerebral hematoma']


abstract: To evaluate the antihypertensive effects of @entity3593 , a renally excreted angiotensin-converting enzyme inhibitor, we assessed supervised administration of the drug after hemodialysis (HD) three times weekly. Blood pressure (BP) was assessed by interdialytic 44-hour ambulatory BP (ABP) monitoring, and endocrine responses were assessed by plasma @entity916 activity (PRA) before and after dialysis. @entity3593 dose was titrated at biweekly intervals. If this was not effective after full titration ( @entity3593 to 40 mg three times weekly), ultrafiltration was added to reduce dry weight. The primary outcome variable was change in BP from the end of the run-in period to the end of the study. No change in mean ABP was noted during run-in. However, mean 44-hour ABP decreased from 149 +/- 14 (SD)/84 +/- 9 to 127 +/- 16/73 +/- 9 mm Hg, a decrease of 22/11 mm Hg (P < 0.001) at final evaluation. Of 11 @entity1 who completed the trial, only 2 @entity1 had systolic @entity101 (>/=135 mm Hg) and 1 @entity1 had diastolic @entity101 (>/=85 mm Hg) at the final visit. Four @entity1 were administered 10 mg of @entity3593 ; 5 @entity1 , 20 mg; and 2 @entity1 , 40 mg; only 1 of these @entity1 required ultrafiltration therapy. There was a persistent antihypertensive effect over 44 hours. BP reduction was achieved without an increase in intradialytic symptomatic or asymptomatic @entity551 episodes. PRA increased in response to dialysis, as well as @entity3593 . In conclusion, supervised @entity3593 therapy is effective in controlling @entity101 in chronic HD @entity1 . This may be related to blockade of @entity2178 generation by kidneys despite the loss of excretory function.

title: XXXX therapy for hemodialysis @entity101 : hemodynamic and endocrine responses.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2178 :: ('183', 'Gene') :: ['angiotensin II']

entities_list: @entity3593 :: ('MESH:D017706', 'Chemical') :: ['Lisinopril', 'lisinopril']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotensive']

answer: @entity3593 :: (MESH:D017706,Chemical) :: ['Lisinopril']


abstract: Infections are a major cause of morbidity and mortality in chronic hemodialysis @entity1 . This single center prospective study was carried out to determine the incidence and risk factors for @entity281 in hemodialysis @entity1 and plan appropriate strategies to reduce the risk of @entity281 . A total of 84 consecutive @entity1 who were initiated on hemodialysis over a 2-year period were followed until they either received a kidney transplant or died. In our hospital, as a policy, @entity1 are offered hemodialysis as a bridge therapy to a kidney transplant. The mean duration of follow up was 3 months (range 1-11.8 months). The factors associated with at least one episode of @entity281 were evaluated. Statistical analysis was done by multivariate stepwise logistic regression method. Fifty-one @entity1 had a total of 57 episodes (67.8%) of @entity281 . Of the 44 episodes of acute @entity2348 , vascular access exit site @entity281 was the commonest followed by @entity295 (13 @entity1 , 29.5%). @entity794 was the commonest bacterial isolate observed in 14 @entity1 . On multivariate analysis, three risk factors for @entity281 were identified: (1) nonarteriovenous fistula (AVF) vascular access for hemodialysis (p = 0.02), (2) increased number of hemodialysis sessions (p = 0.03), and (3) lower serum @entity460 level (p = 0.02). NonAVF vascular access was found to be the most important risk factor for @entity281 in hemodialysis @entity1 . Creation of an @entity292 , preferably at an early stage, appears beneficial for minimizing the risk of @entity281 even in @entity1 who are on short-term hemodialysis as a bridge therapy towards a kidney transplant.

title: Role of vascular access as a risk factor for XXXX in hemodialysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['AV fistula']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

answer: @entity281 :: (MESH:D007239,Disease) :: ['infections']


abstract: BACKGROUND: To confirm the hypothesis that reducing the interval between surgery and adjuvant chemotherapy could improve prognosis, a randomized multicentric study of adjuvant perioperative chemotherapy (POC) in @entity0 was initiated. METHODS: A total of 552 @entity1 were randomized to evaluate whether the addition of POC to standard adjuvant treatment significantly improved outcome. @entity1 were stratified according to menopausal status, with 362 @entity1 in the postmenopausal group and 192 @entity1 in the premenopausal group. Premenopausal @entity1 with positive axillary nodes, negative hormonal receptors, or grade 3 @entity5 received adjuvant @entity2664 -based chemotherapy. Node-negative premenopausal @entity1 with grade 1 or 2 @entity5 expressing hormonal receptors received no standard adjuvant treatment. All postmenopausal @entity1 received hormonal therapy ( @entity440 20 mg/day for 3 years). The perioperative regimen was a 14 mg/m(2) @entity2664 infusion at the end of @entity5 excision. RESULTS: With a median follow-up of 6.1 years, this study showed no significant advantage of POC on overall survival, disease-free survival, or @entity3 -free survival for the total cohort or for the premenopausal and postmenopausal groups. CONCLUSIONS: POC was a safe procedure in this study. However, the addition of POC to standard adjuvant treatment offered no benefit in @entity0 adjuvant treatment.

title: Randomized multicentric study of perioperative chemotherapy with XXXX in early @entity0 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity2664 :: (MESH:D008942,Chemical) :: ['mitoxantrone']


abstract: OBJECTIVES: @entity1 from Minority Ethnic groups tend to present late to @entity303 services, often in crisis. Culture-specific barriers to help-seeking seem to underlie this. We sought to determine these barriers to timely help-seeking for @entity303 among @entity1 from South Asian backgrounds and what the features of an intervention to overcome them would be. STUDY DESIGN: Qualitative study to delineate barriers to and facilitators of help-seeking for South Asian adults with @entity303 through focus groups and individual interviews. SETTING: Community settings in and around Greater London. @entity1 : To achieve a maximum variation sample, we purposively recruited 53 English or Bengali speaking South Asian adults without a known diagnosis of @entity303 through community centres and snowballing. RESULTS: @entity1 ranged in age from 18 to 83   years, were mostly female and were 60% Bangladeshi. We recruited @entity1 from different religions and occupational backgrounds and included those with experience of caring for someone with @entity303 as well as those without this experience. @entity1 identified four main barriers to timely diagnosis: barriers to help-seeking for @entity2414 ; the threshold for seeking help for @entity2414 ; ways to overcome barriers to help-seeking; what features an educational resource should have. CONCLUSIONS: We have identified the features of an intervention with the potential to improve timely @entity303 diagnosis in South Asians. The next steps are to devise and test such an intervention.

title: What would encourage help-seeking for XXXX among UK-based South Asians? A qualitative study.

entities_list: @entity1 :: ('9606', 'Species') :: ['People', 'Participants', 'PARTICIPANTS', 'people']

entities_list: @entity2414 :: ('MESH:D008569', 'Disease') :: ['memory problems']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

answer: @entity2414 :: (MESH:D008569,Disease) :: ['memory problems']


abstract: BACKGROUND: Intraoperative cell salvage (ICS), hereby referred to 'mechanical red cell salvage', has been widely used and proven to be an effective way to reduce or avoid the need for allogeneic red blood cells (RBCs)transfusion and its associated complications in surgeries involving major @entity190 . However, little is known about the influence of this technique on the functional state of salvaged RBCs. Furthermore, there are no articles that describe the change of free hemoglobin (fHb) in salvage blood during storage, which is a key index of the quality control of salvaged blood. Therefore, in this study, the influence of ICS on the function of salvaged RBCs and the changes of salvaged RBCs during storage were studied with respect to the presence of @entity7672 affinity (recorded as a P50 value) and the level of @entity6297 ( @entity6297 ) and fHb by comparing salvaged RBCs with self-venous RBCs and 2-week-old packed RBCs. METHODS: Fifteen @entity1 undergoing off-pump coronary artery bypass grafting (OPCAB) surgery were enrolled. Blood was collected and processed using a Dideco Electa device. The level of P50, 2, 3-DPG and fHB from salvaged RBCs, venous RBCs and 2-week-old packed RBCs was measured. We also measured the changes of these indicators among salvaged RBCs at 4  h (storage at 21-24   C) and at 24  h (storage at 1-6    C). RESULTS: The P50 value of salvaged RBCs at 0  h (28.77        0.27  mmHg) was significantly higher than the value of venous RBCs (27.07        0.23  mmHg, p   =   0.000) and the value of the 2-week-old packed RBCs (16.26        0.62  mmHg, p   =   0.000). P50 value did not change obviously at 4  h (p   =   0.121) and 24  h (p   =   0.384) compared with the value at 0  h. The 2, 3-DPG value of salvaged RBCs at 0  h (17.94        6.91   mol/g Hb) was significantly higher than the value of venous RBCs (12.73        6.52  mmHg, p   =   0.007) and the value of the 2-week-old packed RBCs (2.62        3.13  mmHg, p   =   0.000). The level of 2, 3-DPG slightly decreased at 4  h (p   =   0.380) and 24  h (p   =   0.425) compared with the value at 0  h. Percentage of @entity2142 of the salvaged blood at 0  h(0.51        0.27  %) was significantly higher than the level of venous blood (0.07        0.05  %, p   =   0.000) and the value of 2-week-old packed RBCs (0.07        0.05  %, p   =   0.000), and reached 1.11        0.42  % at 4  h (p   =   0.002) and 1.83        0.77  % at 24  h (p   =   0.000). CONCLUSIONS: The @entity26 transport function of salvaged RBCs at 0  h was not influenced by the cell salvage process and was better than that of the venous RBCs and 2-week-old packed RBCs. At the end of storage, the @entity26 transport function of salvaged RBCs did not change obviously, but percentage of @entity2142 significantly increased.

title: @entity26 carrying capacity of salvaged blood in XXXX undergoing off-pump coronary artery bypass grafting surgery: a prospective observational study.

entities_list: @entity6297 :: ('MESH:D019794', 'Chemical') :: ['2, 3-diphosphoglycerate', '2, 3-DPG']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity7672 :: ('CHEBI:7861', 'Chemical') :: ['oxyhemoglobin']

entities_list: @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: OBJECT The present study was conducted to investigate whether microbleeds or microinfarcts are associated with @entity2204 ( @entity2204 ) gene polymorphisms in @entity1 with @entity7025 ( @entity7025 ), and if so, whetherAPOE gene polymorphisms are also associated with @entity64 type in @entity1 with @entity7025 . METHODS This cross-sectional, multicenter study included 86 consecutive @entity1 with @entity7025 who underwent T2*-weighted gradient echo or susceptibility-weighted MR imaging and 83 healthy control volunteers. Baseline clinical and radiological characteristics were recorded at diagnosis, and inter- and intragroup differences in the @entity2204 genotypes were assessed. Multivariate binary logistic regression models were used to determine the association factors for @entity21374 ( @entity21374 ) and hemorrhagic presentation in @entity1 with @entity7025 . RESULTS There was no difference in @entity2204 gene polymorphism and the incidence of @entity21374 between @entity1 with @entity7025 and healthy controls (p > 0.05). In the @entity7025 group, 7 (8.1%) @entity1 had microbleeds and 32 (37.2%) @entity1 had microinfarcts. Microbleeds were more frequently identified in @entity1 with hemorrhagic-type than in nonhemorrhagictype @entity7025 (p = 0.003). @entity2204 genotypes differed according to the presence of microbleeds (p = 0.024). @entity2204 or   4 carriers also experienced microbleeds more frequently than @entity2204 /  3 carriers (p = 0.013). In the multivariate regression analysis in @entity1 with @entity7025 , microbleeds were significantly related to @entity2204 or   4 carrier status (OR 7.86; 95% CI1.20-51.62; p = 0.032) and @entity438 (OR 17.31; 95% CI 2.09-143.57; p = 0.008). Microinfarcts were independently associated with @entity101 (OR 3.01; 95% CI 1.05-7.86; p = 0.007). Hemorrhagic presentation was markedly associated with microbleeds (OR 10.63; 95% CI 1.11-102.0; p = 0.041). CONCLUSIONS These preliminary results did not show a difference in @entity2204 gene polymorphisms between @entity1 with @entity7025 and healthy @entity1 . However, they imply that @entity2204 gene polymorphisms may play certain roles in the presence of microbleeds but not microinfarcts in @entity1 with @entity7025 . A further confirmatory study is necessary to elucidate the effect of @entity2204 gene polymorphisms and @entity21374 on the future incidence of @entity64 in @entity1 with @entity7025 .

title: Association of XXXX gene polymorphism with @entity21374 and @entity64 type in @entity7025 : a preliminary study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity21374 :: ('MESH:C564372', 'Disease') :: ['small-vessel lesions', 'SVLs']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity2204 :: ('348', 'Gene') :: ['APOE   3', 'apolipoprotein E', 'APOE', 'APOE   2']

entities_list: @entity7025 :: ('MESH:D009072', 'Disease') :: ['moyamoya disease', 'MMD']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['cerebral aneurysm']

answer: @entity2204 :: (348,Gene) :: ['apolipoprotein E']


abstract: This study aimed to explore the molecular mechanism in @entity5 invasion and @entity3 . The expression of @entity5379 ( @entity1476 , @entity1495 ), tissue inhibitor-1 of matrix metalloproteinase ( @entity2843 ), cell adhesion molecule 44 variant 6 (CD44v6), @entity1722 and @entity876 was investigated in 154 @entity1 with @entity213 (SCC) by ABC and ImmunoMax immunohistochemical method. Their clinical relevance and correlation were analysed. The expression of @entity1476 , @entity1495 , @entity2843 , CD44v6, @entity1722 /neu and @entity876 was found in @entity5 cells in 87.01%, 85.71%, 68.18%, 98.05%, 55.19% and 50.65% cases respectively. Linear regression and correlation analysis revealed that there was close positive relationship (P<0.05) between the expression of @entity1476 and @entity1495 , @entity2843 and CD44v6, @entity1722 and @entity1495 , @entity1476 and @entity876 . Up-regulation of @entity1476 was accompanied by @entity1442 stage (P<0.01). There was also a trend of @entity1476 expression being related with @entity5 @entity3 . Increased expression of @entity1722 was found in @entity1 with @entity5 recurrence(P<0.05). The expression of @entity2843 was higher in @entity5 than that in @entity5 , and higher in keratinizing and non-keratinizing SCC than that in basaloid SCC(P<0.05). These findings suggested that @entity1476 and @entity1495 , @entity1722 and @entity1495 , @entity1476 and @entity876 had a coordinate function in aggression of @entity5 ; that @entity1476 had a more important function than @entity1495 in @entity5 invasion and @entity3 ; and that @entity1722 might serve as a biomarker for poor prognosis in @entity213 .

title: Correlation of XXXX and CD44 variant 6 in head and neck @entity5 @entity3 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'laryngeal cancer', 'pharyngeal cancer', 'cancer']

entities_list: @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC', 'head and neck squamous cell carcinoma']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced T']

answer: @entity5379 :: (4313;4318,Gene) :: ['matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase']


abstract: @entity842 (NO) functions as a cell-signaling molecule in plants. In particular, a role for NO in the regulation of @entity68 homeostasis and in the plant response to toxic metals has been proposed. Here, we investigated the synthesis and the role of NO in plants exposed to @entity3409 ( @entity3280 ), a nonessential and toxic metal. We demonstrate that @entity3280 induces NO synthesis in roots and leaves of @entity958 ( @entity958 ) seedlings. This production, which is sensitive to NO synthase inhibitors, does not involve @entity1507 reductase and @entity28316 but requires @entity10039 , encoding a major plasma membrane transporter for @entity68 but also @entity3280 . By analyzing the incidence of NO scavenging or inhibition of its synthesis during @entity3280 treatment, we demonstrated that NO contributes to @entity3280 -triggered inhibition of root growth. To understand the mechanisms underlying this process, a microarray analysis was performed in order to identify NO-modulated root genes up- and down-regulated during @entity3280 treatment. Forty-three genes were identified encoding proteins related to @entity68 homeostasis, proteolysis, @entity1568 assimilation/metabolism, and root growth. These genes include @entity10039 . Investigation of the metal and ion contents in @entity3280 -treated roots in which NO synthesis was impaired indicates that @entity10039 up-regulation by NO was consistently correlated to NO's ability to promote @entity3280 accumulation in roots. This analysis also highlights that NO is responsible for @entity3280 -induced inhibition of root @entity141 accumulation. Taken together, our results suggest that NO contributes to @entity3280 @entity137 by favoring @entity3280 versus @entity141 uptake and by initiating a cellular pathway resembling those activated upon @entity68 deprivation.

title: @entity842 contributes to @entity3409 @entity137 in @entity958 by promoting XXXX accumulation in roots and by up-regulating genes related to @entity68 uptake.

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis thaliana', 'Arabidopsis']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric oxide']

answer: @entity3409 :: (MESH:D002104,Chemical) :: ['cadmium']


abstract: @entity1911 classically displays a variety of rather benign symptoms, such as @entity10 , palpitations, and sweating, although severe cardiac manifestations have been described. We report a case of @entity1911 -induced @entity661 leading to shock and @entity1167 successfully treated with extracorporeal membrane oxygenation (ECMO) as a bridge to pharmacological therapy and curative adrenalectomy. A previously healthy 46-year-old @entity1 presented to the emergency department with @entity490 , @entity1353 , @entity390 , and @entity391 . Clinical evaluation revealed @entity177 with @entity519 and severe @entity520 . Computed tomography (CT) scan showed @entity3126 and a left adrenal mass. Transthoracic echocardiography (TTE) displayed severe @entity1002 with inverted takotsubo contractile pattern. Despite mechanical ventilation and inotropic and vasopressor support, asystolic @entity1167 ensued. The @entity1 was resuscitated using manual chest compressions followed by venoarterial ECMO. Repeated TTEs demonstrated resolution of the @entity296 within a few days. Laboratory results indicated @entity8 , and CT scan of the brain displayed @entity1188 . Biochemical testing and radionuclide scintigraphy confirmed a @entity1911 . Pharmacological adrenergic blockade was instituted prior to delayed adrenalectomy after which the diagnosis was histopathologically verified. The @entity1 recovered after rehabilitation. We conclude that @entity1911 should be considered in @entity1 presenting with unexplained cardiovascular compromise, especially if they display (inverted) takotsubo contractile pattern. Timely, adequate management might involve ECMO as a bridge to pharmacological therapy and curative surgery.

title: @entity1911 -Induced Inverted Takotsubo-Like XXXX Leading to Cardiogenic Shock Successfully Treated With Extracorporeal Membrane Oxygenation.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'patient']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['transient renal and hepatic dysfunction']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy']

entities_list: @entity3126 :: ('MESH:D011654', 'Disease') :: ['pulmonary edema']

entities_list: @entity1911 :: ('MESH:D010673', 'Disease') :: ['pheochromocytoma', 'Pheochromocytoma']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['cardiorespiratory failure']

entities_list: @entity520 :: ('MESH:D000138', 'Disease') :: ['metabolic acidosis']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['occipital infarctions']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['inverted takotsubo-like cardiomyopathy']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular dysfunction']

answer: @entity296 :: (MESH:D009202,Disease) :: ['Cardiomyopathy']


abstract: @entity2338 ( @entity2338 ) related to the vertebrate @entity4059 ( @entity4059 ) have been identified in diverse insect species. In the @entity9222 , @entity9222 , the @entity4059 -like @entity2338 ( @entity4059 / @entity2338 ) is localized in the same neurosecretory cells as the Ovary Maturating Parsin (OMP), a neurohormone that stimulates oocyte growth, vitellogenesis and hemolymph ecdysteroid levels in adult female locusts. In this study, we investigated whether @entity4059 -like @entity2338 can influence feeding and reproduction in the desert locust, Schistocerca gregaria. We identified two highly similar S. gregaria @entity4059 -like @entity2338 precursor cDNAs, each of which also encodes an OMP isoform. Alignment with other insect @entity4059 -like @entity2338 precursors shows relatively high conservation of the @entity4059 / @entity2338 sequence while the precursor region corresponding to OMP is not well conserved. Quantitative real-time RT-PCR revealed that the precursor transcripts mainly occur in the central nervous system and their highest expression level was observed in the brain. Injection of locust @entity4059 / @entity2338 caused a significantly reduced food intake, while RNAi knockdown stimulated food intake. Therefore, our data indicate that @entity4059 -like @entity2338 induces satiety. Furthermore, injection of @entity4059 / @entity2338 in adult females retarded oocyte growth and caused lower ecdysteroid titers in hemolymph and ovaries, while RNAi knockdown resulted in opposite effects. The observed effects of @entity4059 / @entity2338 may be part of a wider repertoire of neurohormonal activities, constituting an integrating control system that affects food intake and excretion, as well as anabolic processes like oocyte growth and ecdysteroidogenesis, following a meal. Our discussion about the functional relationship between @entity4059 / @entity2338 and OMP led to the hypothesis that @entity30153 may possibly act as a monitoring peptide that can elicit negative feedback effects.

title: XXXX -like diuretic hormone negatively affects both feeding and reproduction in the desert locust, Schistocerca gregaria.

entities_list: @entity2338 :: ('MESH:D004393', 'Disease') :: ['DH', 'Diuretic hormones']

entities_list: @entity9222 :: ('7004', 'Species') :: ['migratory locust', 'Locusta migratoria']

entities_list: @entity4059 :: ('MESH:D007020', 'Disease') :: ['CRF', 'Corticotropin Releasing Factor']

answer: @entity4059 :: (MESH:D007020,Disease) :: ['CRF']


abstract: A 74-year-old @entity1 sustained a @entity174 of the distal radius with an additional @entity174 of the styloid process of the ulna due to a fall. After reduction under local anesthesia immobilization treatment in a forearm cast was initiated. Despite increasing secondary dislocation during radiological x-ray follow-up control, the bone was described as correctly aligned by the treating physician and non-operative treatment was continued. After a total treatment period of 9  months including 7  months of physiotherapy the @entity1 still presented a limited range of motion and local soft tissue swelling of the right wrist. The @entity1 filed a complaint for wrong treatment of the @entity174 resulting in severe @entity158 and considerable @entity85 leading to a significant handicap during activities of daily living. The expert opinion of the arbitration board ascertained a case of medical malpractice in terms of the indications. Due to the initial presence of criteria of radiological instability, an operative treatment had already been indicated at the first presentation. In addition, secondary dislocation during radiological follow-up examination should have led to conversion of treatment in favor of surgery. The arbitration board furthermore concluded that iatrogenic malpractice led to a severe @entity85 which would result in a loss of grip strength and future arthritic deformation of the wrist. Legal aspects of the case are discussed.

title: [Conservative treatment of XXXX : Consequences of an uncritical follow-up.]

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['deformity of the right wrist']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['distal radius fracture', 'fracture']

answer: @entity174 :: (MESH:D050723,Disease) :: ['distal radius fracture']


abstract: Forty-five @entity1 with soft tissue @entity242 received additional wide resections after they were treated with simple excision by a primary physician. Of the @entity1 in the current study, 26 were male and 19 were female; all were treated between 1986 and 1998 for @entity8650 . The mean followup was 7.1 +/- 3.4 years. The mean time from first excision to additional wide resection was 8 weeks, and for 90% of the @entity1 it was within 12 weeks. In deciding the surgical margin for an additional operation, enhanced computed tomography scans and magnetic resonance images were done. Four (8.8%) @entity1 had local recurrences that required a second resection and had no evidence of disease at latest followup. Four (8.8%) @entity1 had distant metastases but did not have local recurrences. Three @entity1 died of lung metastases. The overall 5-year survival rate of the @entity1 was 93%, and the overall 5-year disease-free rate was 84%. It seems that @entity5 treated adequately by wide resection in an additional operation have results as @entity5 treated with a primary wide resection.

title: Additional wide resection of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['good as tumors', 'tumors']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcomas']

entities_list: @entity8650 :: ('MESH:D012983', 'Disease') :: ['malignant soft tissue tumors']

answer: @entity8650 :: (MESH:D012983,Disease) :: ['malignant soft tissue tumors']


abstract: BACKGROUND AND PURPOSE: To determine the frequency of @entity33 and associated outcomes in @entity1 receiving radiotherapy ( @entity138 ) for @entity135 through a systematic review of recently published literature. MATERIALS AND METHODS: According to the study protocol, databases were searched for randomized clinical trials (English only, 1996-1999) of @entity1 with @entity135 receiving @entity138 with or without chemotherapy that reported one or more outcomes of interest. RESULTS: Thirty-three studies (n=6181 @entity1 ) met inclusion criteria. @entity33 was defined using a variety of scoring systems. The mean incidence was 80%. Over one-half of @entity1 (56%) who received altered fractionation @entity138 ( @entity138 ) experienced severe @entity33 (grades 3-4) compared to 34% of @entity1 who received conventional @entity138 . Rates of hospitalization due to @entity33 , reported in three studies (n=700), were 16% overall and 32% for @entity138 @entity1 . Eleven percent of @entity1 had @entity138 regimens interrupted or modified because of @entity33 in five studies (n=1267) reporting this outcome. Data insufficiency or heterogeneity prohibited analysis of @entity33 severity and other associated outcomes, such as @entity158 , @entity1282 and opioid use. CONCLUSIONS: @entity33 is a frequent, severe @entity137 in @entity1 treated with @entity138 for @entity135 . While it appears that @entity33 may lead to hospitalization and treatment interruptions, its overall impact on outcomes has not been adequately investigated.

title: @entity33 incidence, severity and associated outcomes in @entity1 with XXXX receiving radiotherapy with or without chemotherapy: a systematic literature review.

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis', 'Mucositis']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['oral pain']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

answer: @entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']


abstract: BACKGROUND: The 5-tier Emergency Severity Index (ESI) score is a well-accepted, validated triage tool with good interrater reliability. Parental perception of illness severity has not been compared to ESI score. OBJECTIVE: This study compares parental assessment of severity of illness to triage nurse acuity. DESIGN: Prospective and descriptive. SETTING: Large, urban pediatric @entity341 ( @entity341 ). @entity1 : Parents/guardians of @entity1 younger than 18 years. INTERVENTION: The triage nurse assigned an ESI score, and the parent/ guardian assigned all @entity1 a severity score on a scale of 1 to 5 (1, most sick and 5, least sick). Mean severity scores were compared between the groups. RESULTS: There were 142 @entity1 with a mean @entity1 age of 6.15 years. The mean @entity1 and nurse severity scores were 3.01 and 3.35, respectively, with an intraclass correlation coefficient of 0.203 (P = 0.008). Most frequently, the parent/guardian and triage nurse assigned the same score (n = 44, 31%). Seventy-six percent of the parent/ guardian scores were within 1 point of the triage nurse score. CONCLUSIONS: Close agreement exists between parent/guardian and nurse ESI scores, illustrating objectivity in parent/guardian assessments. This study provides a springboard for future studies regarding @entity341 use after educating families on @entity341 triage.

title: A comparison of parental and nursing assessments of level of illness or injury in a pediatric XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'participant', 'patient', 'PARTICIPANTS']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['emergency department', 'ED']

answer: @entity341 :: (MESH:D004630,Disease) :: ['emergency department']


abstract: OBJECTIVE: The purpose of this study is to present the role of embolization in the treatment of @entity8 ( @entity359 ) in cases of @entity548 and to prevent @entity548 . METHODS: Over a period of 10 years, 35 AMLs in 34 @entity1 , recruited in two medical centers, were treated with embolization: 16/35 @entity359 were treated urgently to stop @entity548 , and 19/35 @entity359 had preventive embolization. Six @entity1 were completely asymptomatic and 13 had a history of previous @entity1410 or @entity812 . Catheterization was highly selective in all cases (coaxial microcatheter in 19 cases), and for embolization we used nonresorbable microparticles, coils, and @entity167 . RESULTS: When @entity1 presented with @entity548 , embolization was efficient in 80% of cases; another embolization was necessary in two cases, and surgery in two others. In six of these cases, surgery was planned and done at a later date. When treatment was preventive, one embolization was necessary in 17 cases, and two embolizations per case were necessary in the other two. Over a period of 18 months of follow-up, we observed a 28% decrease in @entity5 volume; four @entity1 were treated by surgery at a later date. CONCLUSION: Embolization is the technique of choice to treat a @entity548 @entity359 urgently. When preventive treatment is considered, in symptomatic or asymptomatic @entity359 , embolization can be an alternative for surgery, but more data is needed to specify its proper place in the management of these @entity5 .

title: [Role of embolization in XXXX ].

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal angiomyolipoma']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'bleeding', 'acute bleeding']

entities_list: @entity167 :: ('CHEBI:16236', 'Chemical') :: ['alcohol']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity812 :: ('MESH:D021501', 'Disease') :: ['flank pain']

answer: @entity8 :: (MESH:D007674,Disease) :: ['renal angiomyolipomas']